US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Alamar Biosciences / Equity Capital Markets

<ul>
<li>Alamar Biosciences IPO priced at $17.00 after being upsized; opened up 32.9% reflecting strong institutional demand.</li>
<li>Deal was ~12x oversubscribed with highly concentrated allocations; top 25 accounts received ~80% of shares.</li>
<li>Revenue-Generating proteomics platform scaling rapidly, with $74.2M revenue and expanding margins driving investor interest.</li>
</ul>


Alamar Biosciences IPO priced at $17.00 after being upsized; opened up 32.9% reflecting strong institutional demand.
Deal was ~12x oversubscribed with highly concentrated allocations; top 25 accounts received ~80% of shares.
Revenue-Generating proteomics platform scaling rapidly, with $74.2M revenue and expanding margins driving investor interest.


Alamar Biosciences (ALMR): Scarcity and Growth Power Strong First-Day Rally for Proteomics Platform

<ul>
<li>Revenue nearly tripled to $74.2M in 2025 with expanding margins, highlighting strong commercialization and early operating leverage.</li>
<li>IPO multiple-times oversubscribed with strong institutional demand; tight float may support favorable aftermarket performance.</li>
<li>Backed by top-tier investors with $300M+ raised; large and growing $50B+ market opportunity supports sustained high-growth outlook.</li>
</ul>


Revenue nearly tripled to $74.2M in 2025 with expanding margins, highlighting strong commercialization and early operating leverage.
IPO multiple-times oversubscribed with strong institutional demand; tight float may support favorable aftermarket performance.
Backed by top-tier investors with $300M+ raised; large and growing $50B+ market opportunity supports sustained high-growth outlook.


Alamar Biosciences (ALMR): Bio-Platform Company Scales, Draws Heavy IPO Interest

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>✅ IPO PROPHET RATING: 7.78/10 🏦 Deal Quality &amp; Underwriters: 8.4/10 Alamar Biosciences is coming to market offering approximately 9.4 million shares at $15 to $17, targeting a valuation around $1.1 billion.</li><li>The company operates in precision proteomics, developing ultra-sensitive platforms capable of detecting low-abundance proteins for applications across early disease detection, drug development, and diagnostics.</li><li>The deal is being marketed to a concentrated base of healthcare-focused institutional investors during an active but selective biotech IPO window.</li></ul>

✅ IPO PROPHET RATING: 7.78/10 🏦 Deal Quality &amp; Underwriters: 8.4/10 Alamar Biosciences is coming to market offering approximately 9.4 million shares at $15 to $17, targeting a valuation around $1.1 billion.The company operates in precision proteomics, developing ultra-sensitive platforms capable of detecting low-abundance proteins for applications across early disease detection, drug development, and diagnostics.The deal is being marketed to a concentrated base of healthcare-focused institutional investors during an active but selective biotech IPO window.

<ul><li>Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial public offering, offering 9.375 million shares at a price range of $15.00 to $17.00 , implying a midpoint price of $16.00 and an estimated market capitalization of roughly $1.0 billion based on approximately 64.9 million shares outstanding post-offering .</li><li>The company plans to list on the Nasdaq Global Select Market under the ticker ALMR , with lead underwriters including J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners, and Stifel. </li><li>Alamar is a commercial-stage life sciences company focused on advancing precision proteomics, a rapidly emerging field centered on measuring protein biomarkers to enable earlier and more accurate disease detection.</li></ul>

Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial public offering, offering 9.375 million shares at a price range of $15.00 to $17.00 , implying a midpoint price of $16.00 and an estimated market capitalization of roughly $1.0 billion based on approximately 64.9 million shares outstanding post-offering .The company plans to list on the Nasdaq Global Select Market under the ticker ALMR , with lead underwriters including J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners, and Stifel. Alamar is a commercial-stage life sciences company focused on advancing precision proteomics, a rapidly emerging field centered on measuring protein biomarkers to enable earlier and more accurate disease detection.

Alamar Biosciences Targets ~$150M IPO as Precision Proteomics Platform Scales Toward Diagnostics

<ul>
<li>IPO terms set for $15.00–$17.00 per share, targeting ~$1.1B valuation and ~$133M in proceeds to scale commercial, manufacturing, and R&amp;D operations.</li>
<li>Commercial-Stage proteomics company generating $74.2M revenue in 2025, leveraging proprietary NULISA platform for ultra-sensitive biomarker detection across research and diagnostics.</li>
<li>Strong investor backing and momentum with $300M+ raised, Qiming Ventures as largest holder (16.2%), and IPO expected to trade April 17.</li>
</ul>


IPO terms set for $15.00–$17.00 per share, targeting ~$1.1B valuation and ~$133M in proceeds to scale commercial, manufacturing, and R&amp;D operations.
Commercial-Stage proteomics company generating $74.2M revenue in 2025, leveraging proprietary NULISA platform for ultra-sensitive biomarker detection across research and diagnostics.
Strong investor backing and momentum with $300M+ raised, Qiming Ventures as largest holder (16.2%), and IPO expected to trade April 17.


Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alamar Biosciences (ALMR US)

Alamar Biosciences (ALMR): Scarcity and Growth Power Strong First-Day Rally for Proteomics Platform

Alamar Biosciences IPO priced at $17.00, opened up 32.9% due to strong institutional demand and rapid revenue growth in proteomics platform.

IPO Boutique

Alamar Biosciences (ALMR): Bio-Platform Company Scales, Draws Heavy IPO Interest

Strong commercialization and institutional demand drive revenue growth and IPO success for company backed by top-tier investors in a large market...

IPO Boutique

IPO Rating: Alamar Bioscienes, Inc.

✅ IPO PROPHET RATING: 7.78/10 🏦 Deal Quality & Underwriters: 8.4/10 Alamar Biosciences is coming to market offering approximately 9.4 million...

IPO Prophet

Alamar Biosciences Targets ~$150M IPO as Precision Proteomics Platform Scales Toward Diagnostics

Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial public offering, offering 9.375 million shares...

IPO Prophet

Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO

Proteomics company sets IPO terms at $15.00–$17.00 per share, targeting $1.1B valuation to scale operations and leverage NULISA platform for...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Alamar Biosciences (ALMR): Scarcity and Growth Power Strong First-Day Rally for Proteomics Platform

​Alamar Biosciences IPO priced at $17.00, opened up 32.9% due to strong institutional demand and rapid revenue growth in proteomics platform.

IPO Boutique

Alamar Biosciences (ALMR): Bio-Platform Company Scales, Draws Heavy IPO Interest

​Strong commercialization and institutional demand drive revenue growth and IPO success for company backed by top-tier investors in a large market...

IPO Boutique

IPO Rating: Alamar Bioscienes, Inc.

✅ IPO PROPHET RATING: 7.78/10 🏦 Deal Quality & Underwriters: 8.4/10 Alamar Biosciences is coming to market offering approximately 9.4 million...

IPO Prophet

Alamar Biosciences Targets ~$150M IPO as Precision Proteomics Platform Scales Toward Diagnostics

Alamar Biosciences, Inc. (“ALMR”) is seeking to raise approximately $150.0 million in its initial public offering, offering 9.375 million shares...

IPO Prophet

Alamar Biosciences (ALMR): Revenue Generating Protein Detection Platform Sets Terms for IPO

​Proteomics company sets IPO terms at $15.00–$17.00 per share, targeting $1.1B valuation to scale operations and leverage NULISA platform for...

IPO Boutique

Alamar Biosciences IPO priced at $17.00, opened up 32.9% due to strong institutional demand and rapid revenue growth in proteomics platform.

Strong commercialization and institutional demand drive revenue growth and IPO success for company backed by top-tier investors in a large market...

Proteomics company sets IPO terms at $15.00–$17.00 per share, targeting $1.1B valuation to scale operations and leverage NULISA platform for...